Fundamental Analysis of Iradimed Co - Growth / Value Index
IRMD - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 17.19
Price to Book Ratio of 7.53 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 30.18 | 33.09 | -20.89 % | |
Price to Book | 7.61 | 7.57 | 3.86 % | 7.11 |
Price to Sales | 7.99 | 8.58 | -14.78 % | |
Enterprise Value to EBITDA Multiple | 23.30 | 30.32 | 2.43 % |
IRMD - Profitability Highlights
Profitability Analysis
Tremendous increasing trend in Net Profit for last 3 year
Excellent Net Margin for last 3 years
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 25.21%
During the past twelve months, the company has given a strong Return On Asset of 21.10%
During the past twelve months, the company has given a strong Net Margin of 26.48%
All key Trailing Twelve Months Margin growing by 15 %
Piotroski F Score - Stable Value of 4.0
EBITDA is continuously increasing for last 3 Years
Good Return On Capital Employed of 22.86
Low Earning Yield of 3.35 %
EPS decline for last four quarters
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 25.21 | 22.86 | 31.29 % | 5.43 |
Return On Asset | 21.10 | 17.72 | 18.10 % | 4.70 |
Net Profit Margin | 26.48 | 25.93 | 7.73 % | 23.51 |
Operating Profit Margin | 30.70 | 30.38 | 3.61 % | 26.98 |
EBITDA Margin | 30.98 | 25.71 | -15.29 % | 28.07 |
Highlights
Market Cap | 537848 K |
Enterprise Value | 488514 K |
Price/Book TTM | 7.61 |
Outstanding Share | 12664.20 K |
Float/ Outstanding Share | 56.55% |
Dividend Yield | 1.42 % |
Share Holding
Guru Numbers
Price/Graham No | 3.19 |
Peter Lynch Ratio | 0.876 |
Piotroski F Score | 4.00 |
Altman Z Score | 18.23 |
Sloan Ratio | 0.0405 |
Peter Lynch Fair Value | 24.30 |
IRMD - Growth Highlights
Growth Analysis
Tremendous increasing trend in total sale last 3 year
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 67685.33 K | 18.14 % | 0.836 % |
Gross Profit | 51824.54 K | 16.19 % | 0.188 % |
EBITDA | 20967.85 K | 0.079 % | 4.27 % |
Net Profit | 17923.24 K | 27.28 % | 8.88 % |
EPS | 1.41 | 26.41 % | NA |
IRMD - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 92.86
Altman Z Score of 18.07 suggests good Stability
Cash ratio of 3.05
Interest Coverage of 0
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.0060 | 50.43 % | 0.0055 |
Cash Ratio | 3.05 | -55.02 % | |
Quick Ratio | 3.87 | -54.55 % | 7.77 |
Shareholders Equity | 77.50 | -10.04 % | |
Debt to EBITDA | 0.0264 | 45.71 % |
Historical Valuation Ratios of Iradimed Co
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Iradimed Co
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Iradimed Co
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Iradimed Co
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)